CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review - Scorecard - MDSpire

CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review

  • By

  • Sheng-Guang Li

  • Ruohan Yu

  • Lina Zhang

  • Jing Zhang

  • Yadan Zou

  • Ji Li

  • Ting Long

  • Yanfeng Zhang

  • Jing Pan

  • July 1, 2026

  • 0 min

Share

Clinical Scorecard: Systematic Review of CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus: Addressing Overlapping Data

At a Glance

CategoryDetail
ConditionRefractory Systemic Lupus Erythematosus
Key MechanismsCAR-based cellular therapy targeting autoreactive B-lineage cells.
Target PopulationPatients with relapsed or refractory systemic lupus erythematosus, particularly those with renal involvement.
Care SettingClinical research and trials evaluating CAR-based therapies.

Key Highlights

  • CAR-based cellular therapy shows promising remission signals in refractory systemic lupus erythematosus.
  • Overlap-controlled synthesis reduces duplicate counting in this rapidly expanding evidence base.
  • Endpoint-specific proportions are descriptive only and remain limited by sparse exact evaluability.
  • Future trials need harmonised efficacy, immune-reconstitution and immune-effector toxicity endpoints.

Guideline-Based Recommendations

Diagnosis

  • Identify patients with relapsed or refractory systemic lupus erythematosus.

Management

  • Consider CAR-based cellular therapy for patients with severe manifestations, particularly renal involvement.

Monitoring & Follow-up

  • Monitor for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

Risks

  • Be aware of potential severe inflammatory toxicities in selected paediatric or highly inflammatory settings.

Patient & Prescribing Data

Predominantly female, median age 32 years, heavily pretreated.

Autologous CD19 CAR-T and BCMA-containing platforms are most commonly used.

Clinical Best Practices

  • Conduct standardised prospective studies with harmonised efficacy and toxicity endpoints.
  • Utilize overlap-controlled methods to ensure accurate patient-level data synthesis.

Related Resources & Content

Original Source(s)

Related Content